Intranasal pirodavir (R77,975) treatment of rhinovirus colds.
A randomized, double-blind, placebo-controlled trial assessed the therapeutic efficacy of intranasal pirodavir in naturally occurring rhinovirus colds. Adults with symptoms of < or = 2 days' duration were randomly assigned to intranasal sprays of pirodavir (2 mg per treatment) or placebo six times d...
Tallennettuna:
| Julkaisussa: | Antimicrob Agents Chemother |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society for Microbiology (ASM)
1995
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC162529/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/7726484/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.39.2.290 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|
